SBIR/STTR Research Award

Exploiting porcine cytomegalovirus stealth mechanisms

Award identifier 91b186d69c0721d9752a9872067e15c4287c31306e15cddcf67833c92686fea2Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$142,035

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Xenocept, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Pig-to-human xenotransplantation may alleviate the critical shortage of organs available for transplantation. However, hyperacute rejection (HAR), acute vascular rejection (AVR), and cell-mediated rejection pose significant immunological hurdles to making xenotransplantation a clinical reality. Now that pigs lacking a functional alpha-1,3-galactosyltransferase gene have been generated, HAR has been completely eliminated and AVR appears to be substantially reduced. Cell-mediated rejection (i.e., by T cells and NK cells) continues to pose a serious problem. Viruses have evolved a plethora of mechanisms to avoid T cell and NK cell recognition and destruction. The proposed project aims to exploit such "viral stealth" mechanisms for the purpose of xenotransplantation. The focus of the proposed studies will be on porcine cytomegalovirus (PCMV) since it is likely to harbor genes which function optimally in pig cells. Under Specific Aim 1, the complete genome of PCMV will be cloned and sequenced. The goal of Specific Aim 2 is to identify potential immunomodulatory open reading frames (ORFs) of PCMV, first by semi-high throughput assays, and then, for a subset of PCMV ORFs, by more detailed and refined analyses. The Phase I project will be deemed successful when we have identified specific genes from PCMV which impart stealth to pig cells in vitro when exposed to cells from the human immune system.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.